.avif)
SAN DIEGO, July 20, 2012 - Assay Depot LLC today announced the launch of a virtual research laboratory. Developed in partnership with AstraZeneca, the virtual laboratory is a powerful vendor relationship management (VRM) system that gives researchers easy access to a distributed network of thousands of research service providers located inside and outside the company.
"We brought together features of today’s favorite consumer websites to create a virtual laboratory that empowers scientists," stated Kevin Lustig, Assay Depot’s CEO. "A small group of talented scientists can now run an entire drug discovery program, from concept to clinic, from a laptop computer."
The private virtual laboratory (aka Research Exchange) enables researchers to search for research services and vendors, communicate with experts, purchase services, and rate and review services. In one simple and intuitive interface, scientists identify experts, initiate research collaborations, and track entire projects to completion.
Researchers can access the virtual laboratory from anywhere they access the Internet, including tablets and mobile devices. They can view their colleagues’ ratings and reviews, view past transactions and determine at a glance which vendors have current legal agreements.
"The virtual drug discovery era has arrived," said Chris Petersen, Assay Depot’s CIO. "Enabling research scientists to access any service and any expert in just a few mouse clicks can dramatically improve productivity, reduce costs and promote innovation."
A private virtual laboratory enables complete transparency across global research operations while retaining local control over research sourcing decisions. It simplifies legal and compliance verification, standardizes sourcing governance and serves as a versatile all-in-one platform that benefits the entire chain of pharmaceutical stakeholders, including discovery research, supply chain and consumer health.
"By connecting our internal and external science, the virtual laboratory platform is creating a new approach for our scientists to run experiments with an optimal balance of speed, quality, and cost. We look forward to assessing how the virtual laboratory platform impacts and accelerates productivity in the R&D pipeline," said Mike Snowden, Vice President, Discovery Sciences, AstraZeneca.
AstraZeneca:
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com.
.webp)
Scientist.com
Scientist.comは、科学研究のアウトソーシングという複雑な業務のために構築された、世界最大かつ初のプラットフォームです。
私たちは、製薬・バイオテクノロジー企業が、創薬や前臨床研究から臨床開発、製造、メディカルアフェアーズ、そして商業化に至るまで、パイプラインのあらゆる段階を支えるプロバイダーとの関係を構築、管理、拡大できるよう支援しています。一元化されたプラットフォームを通じて、組織は6,000社以上のグローバルなプロバイダーネットワークにアクセスし、調達ワークフローの効率化、コンプライアンスの維持、サプライヤー関係の管理を実現するとともに、データに基づいた洞察を活用して、より迅速かつ的確な意思決定を行うことが可能です。
現在、Scientist.comは世界の製薬企業トップ30社のうち24社を含む130以上のライフサイエンス関連組織を支援しており、業務の複雑さを軽減し、開発期間を短縮し、イノベーションをより迅速に患者へ届けるためのサポートを行っています。私たちの使命は、2050年までに人類のあらゆる疾患を治癒可能にすることです。